CGEM at a glance
Cullinan Therapeutics, Inc. (CGEM, SEC CIK 1789972) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Cullinan Therapeutics, Inc. (CGEM) shares worth $322.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Michaelson Jennifer on November 5, 2026 of 4,000 shares at $12.36 per share.
- In the last 90 days, CGEM insiders reported 0 open-market purchases ($0) and 2 open-market sales ($222K) on Form 4, a net sale of $222K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$222K
- 13F holders
- 26 funds
- $322.6M · +0 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, no product sales, unchanged from Q3 2025
- R&D expense $40.2M vs $42.0M YoY, G&A $12.4M vs $13.6M
- Best pipeline growth: CLN-978 R&D $9.8M vs $5.3M YoY
- Cash, equivalents, and short-term investments $289.6M, long-term investments and interest receivable $24.2M
- Operating cash outflow $127.3M, cash expected to fund operations at least twelve months, additional capital may be needed
Risk Factors
- Newly added SEC compliance risk: non-affiliate market value exceeded $700 million on June 30, 2026
- Reporting transition: SRC status ends after December 31, 2026, with accommodations continuing for 2027 filings
- Regulatory burden: accelerated-filer status could require Section 404(b) auditor attestation beginning December 31, 2027
- Financial risk: additional reporting requirements expected to increase legal, accounting and compliance costs
- Operational risk: expanded public-company obligations could divert management attention from operations
AI summary of the CGEM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
- Detailed results and management commentary available in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Cash and investments $313.8M at September 30, supporting operations into 2029 under the current plan
- Zipalertinib first-line NDA submission underway, with Cullinan eligible for $100M approval milestone and 50/50 U.S. profit share
Item 7.01: Regulation FD Disclosure
- Cullinan announced clinical data from Genrix’s ongoing Phase 1b/2a velinotamig trial in active, refractory moderate-to-severe SLE
- Velinotamig represents a globally licensed, all-indication asset outside Greater China
Item 8.01: Other Events
- Interim Phase 1b/2a data for velinotamig in refractory SLE, with 12 patients treated across three multi-dose cohorts
- Favorable safety profile: no dose-limiting toxicities, ICANS, or Grade 3+ CRS
Item EX-99.1: Item EX-99.1
- Interim Phase 1b/2a data support velinotamig’s autoimmune proof of concept, with meaningful disease improvement in 8 of 9 evaluable SLE patients
- Renal signal particularly strong: 4 of 7 patients with baseline proteinuria achieved complete renal responses within 24 weeks
Item 7.01: Regulation FD Disclosure
- Updated CLN-049 Phase 1 dose-escalation data planned for December ASH meeting
- Data concern relapsed or refractory AML and MDS patients
Item 8.01: Other Events
- Phase 1 CLN-049 data in 87 relapsed/refractory AML or MDS patients support advancing the program into ongoing Phase 2 testing
- Two-step dosing reduced CRS to 26% from 36%, with only Grade 1 or Grade 2 events
Item EX-99.1: Item EX-99.1
- ASH presentations on December 12-15 feature updated CLN-049 Phase 1 AML/MDS data and four total posters across oncology and autoimmune programs
- CLN-049 reports anti-leukemic activity at selected Phase 2 target doses of 6 µg/kg and 12 µg/kg
AI summaries of CGEM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CGEM
Don't miss the next CGEM filing
- Alerts as it files. A push when CGEM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CGEM, by share count.
- Ask anything. An AI agent that reads every CGEM filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Michaelson Jennifer | M | Nov 5, 2026 | 3,805 | - |
| Michaelson Jennifer | Sell | Nov 5, 2026 | 4,000 | $12.36 |
| Michaelson Jennifer | M | Nov 5, 2026 | 3,805 | $4.30 |
| Michaelson Jennifer | M | Sep 8, 2026 | 4,000 | - |
| Michaelson Jennifer | M | Sep 8, 2026 | 4,000 | $4.30 |
| Michaelson Jennifer | Sell | Sep 8, 2026 | 8,000 | $21.57 |
| Michaelson Jennifer | M | Aug 13, 2026 | 30,000 | - |
| Michaelson Jennifer | M | Aug 13, 2026 | 30,000 | $4.30 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$191.1M | -$196.9M | -$241.6M | |
| Net Income | -$153.2M | -$167.4M | -$219.9M | |
| Balance Sheet | ||||
| Total Assets | $484.2M | $621.8M | $448.4M | |
| Equity | $453.7M | $590.3M | $408.7M | |
| ROE | -33.8% | -28.4% | -53.8% | |
| Per Share | ||||
| EPS | $-3.69 | - | - | |
| Cash Flow | ||||
| Operating CF | -$134.3M | -$145.3M | -$175.8M | |
| CapEx | $208K | $0 | $49K | |
Source: XBRL data in Cullinan Therapeutics, Inc. (CGEM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CGEM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $322.6M |
| Q2 2026 | 26 | $418.6M |
| Q1 2026 | 25 | $252.6M |
| Q4 2025 | 23 | $162.8M |
| Q3 2025 | 24 | $104.9M |
| Q2 2025 | 24 | $139.6M |
| Q1 2025 | 21 | $111.3M |
| Q4 2024 | 18 | $167.1M |
- T. Rowe Price Group+265.7K (+7%)
- Invesco Ltd+139.6K (+97%)
- BlackRock+86.5K (+2%)
- Dimensional Fund Advisors+38.1K (+4%)
- Vanguard Capital Management LLC+27.5K (+1%)
- State Street Corp−1.06M (-29%)
- Citadel Advisors LLC−344.6K (-87%)
- Millennium Management−320.6K (-93%)
- Prudential Financial−132.3K (-79%)
- Citigroup−96.1K (-77%)
- Raymond James Financial+98.2K
- FMR LLC (Fidelity)−240.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 187 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CGEM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Nov 6, 2026 | - | - | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Oct 2, 2026 | - | Analysis | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 8-K | Jun 8, 2026 | - | Analysis |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
CGEM SEC filings: frequently asked questions
Are CGEM insiders buying or selling?
In the last 90 days, Cullinan Therapeutics, Inc. (CGEM) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $222,000 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CGEM stock?
As of September 30, 2026, the largest Cullinan Therapeutics, Inc. (CGEM) holders among the 13F filers tracked by SignalX were BlackRock ($81.7 million), T. Rowe Price Group ($62.8 million), Vanguard Capital Management LLC ($40.5 million), State Street Corp ($40.0 million), Dimensional Fund Advisors ($16.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did CGEM report in its latest 8-K?
Cullinan Therapeutics, Inc. (CGEM) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.
What are the latest CGEM SEC filings?
Cullinan Therapeutics, Inc. (CGEM) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 6, 2026.
What is CGEM's SEC CIK number?
Cullinan Therapeutics, Inc. (CGEM)'s SEC Central Index Key (CIK) is 1789972. EDGAR lists every CGEM filing under that number.
Ask anything about CGEM
The research agent reads CGEM's filings, financials, insider trades and 13F holders, then answers with sources.